Sygnature is a leading provider of outsourced drug discovery services to UK and overseas biotech and pharma companies. The company employs over 200 mainly PhD qualified staff who work in partnership with its clients to support them in identifying and developing new molecules in the early stages of their drug development process. Phoenix invested in Sygnature in October 2017.
our partnershipPhoenix will work in partnership with Sygnature’s management team to accelerate growth by expanding the Sygnature’s international reach, broadening the range of services that the business provides to its clients and supporting future acquisition opportunities
"We are extremely proud of our people and our culture at Sygnature which is focused on undertaking leading edge research in drug discovery and providing a great service for our customers. We are excited to be working with Phoenix – our partnership will give us the investment we need to further expand our business and provide a broader range of services for our customers.”
Simon Hirst, CEO, Sygnature